New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
08:10 EDTECYT, MRKMerck Endocyte announce 'positive opinions' for VYNFINIT, FOLCEPRI, NEOCEPRI
Merck (MRK) and Endocyte (ECYT) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued "positive opinions" for the Conditional Marketing Authorisations of VYNFINIT and companion imaging components, imaging agent FOLCEPRI and NEOCEPRI for the treatment of adult patients with folate receptor-positive, platinum-resistant, ovarian cancer, in combination with pegylated liposomal doxorubicin. The applications for Conditional Marketing Authorization for vintafolide, etarfolatide and IV folic acid were submitted based on results in platinum-resistant ovarian cancer patients who express the folate receptor on all target lesions as evaluated in the PRECEDENT Phase 2 study. The CHMP positive opinions will be reviewed by the European Commission. If approved, the EC grants a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway. The EC usually issues a final legally binding decision within three months of a CHMP opinion.
News For MRK;ECYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:31 EDTMRKMerck announces collaboration with American Diabetes Association
Merck announced a collaboration with the American Diabetes Association. The collaboration aims to educate adults with diabetes about their increased risk for potentially serious health problems, including pneumococcal pneumonia, influenza and hepatitis B, making it important for people with Type 1 or Type 2 diabetes to talk to their health care professional about these diseases.
March 25, 2015
07:28 EDTMRKOptions expected to be active
Subscribe for More Information
March 24, 2015
19:40 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
17:02 EDTMRKMerck announces new $10B share repurchase program
Merck announced that its board of directors has authorized additional purchases of up to $10B of Merck’s common stock for its treasury. The treasury stock purchase has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. With this announcement, the company’s total outstanding share repurchase authorization is now approximately $11.7B, which includes approximately $1.7B in authorized repurchases remaining under the program previously announced on May 1, 2013. Merck continues to expect average diluted shares outstanding will be approximately 2.86B in 2015.
17:00 EDTMRKMerck announces new $10B share repurchase program
Subscribe for More Information
16:00 EDTMRKOptions Update; March 24, 2015
iPath S&P 500 VIX Short-Term Futures down 10c to 25.14 Option volume leaders: AAPL TSLA TWTR GILD FB AMAT GOOG C MRK GILD according to Track Data.
08:31 EDTMRKMerck: Phase 3 KEYNOTE-006 study met co-primary endpoints, will be stopped early
Subscribe for More Information
March 23, 2015
09:45 EDTMRKUBS to hold a field trip
Subscribe for More Information
07:17 EDTMRKAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
07:41 EDTMRKAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 16, 2015
15:33 EDTMRKMerck says study shows VYTORIN reduced CV events more than simvastatin alone
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use